30 closest matches · ranked by relevance
Healthy Volunteers
Primary: The Effects of Storage-related RBC Changes on Acetylcholine-stimulated (NO-mediated) Forearm Blood Flow. — 19.02; 18.42; 17.61; 22.89 mL / 100 mL / min
Adverse Effects in the Therapeutic Use of Plasma Substitutes
Primary: Monitoring of Adverse Drug Reactions Caused by the Octaplas™Used for Plasma Exchange. — 0; 5; 3; 8 event
Apheresis Related Hypotension
Primary: Rate of Significant Hypotensive Adverse Events — .035; .051 % of significant hypotensive AEs
Blood Coagulation Disorders
Primary: Amount of Chest Catheter Drainage 24 Hours Postoperatively — 766; 626 mL
Convalescent Plasma · COVID-19 · SARS-CoV 2
Primary: Duration of Oxygenation Support — 7.4 days
Freeze Dried Plasma in Healthy Volunteers
Primary: Safety of Single Infusions of FDP at Increasing Fixed Doses in Normal Healthy Subjects by Evaluating Vital Signs and Laboratory Tests — 4; 4; 4; 4 Participants
Hypofibrinogenemia · Bleeding
Primary: Total Number of RBCs Used Over Admission — 5.8; 6.7 RBC Units
Postoperative Kidney Injury
Primary: Urine Neutrophil Gelatinase-associated Lipocalin (NGAL) [Time Frame: 24 Hours After Surgery] [Designated as Safety Issue: Yes] — 2.9; 4.0; 5.0; 4.7 ng/ml — p=0.15
COVID-19
Primary: Plasma Viscosity — 2.35; 2.47; 1.61; 2.47 cP
Cardiovascular Diseases
Primary: Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at Baseline — 4.87…
Kidney Transplantation
Primary: Post-transplant Biopsy to Identify Rejection Episodes — 2; 3 Episode of rejection
Extracorporeal Membrane Oxygenation
Primary: ECMO Pump Longevity — 187; 131 hours — p=0.39
Liver Disease
Primary: Number of Participants That Reached Targeted International Normalized Ratio (INR) Within ±0.1 After First Fresh Frozen Plasma (FFP) Transfusion Completed. — 7; 17…
SARS-CoV-2 Infection
Primary: Number of Participants With Day 28 Severity Outcomes Using a 7-point Ordinal Scale of Clinical Status — 108; 48; 3; 2 Participants
Liver Surgery · Liver Dysfunction · Coagulopathy
Primary: Number of Participants With Adverse Drug Reactions (e.g., Allergic Reactions, TEs, TEEs (Thromboembolic Events) and Hyperfibrinolytic Events) — 5; 0; 0; 0 participants
Hemmorhagic Shock During Air Medical Transport
Primary: Our Primary Outcome for the Proposal Will be 30 Day Mortality — 53; 89 Participants
Patients Undergoing Any Kind of Surgery
Primary: Number of Different Substitution Solutions Administered — 7827; 1055; 221 participants
Autoimmune Diseases · Renal Disorders · Hematologic Disorders
Primary: Percent Efficiency of Plasma Removal During the Therapeutic Plasma Exchange Procedure — 81.9; 75.2 percentage of plasma removal efficiency — p=<0.001
COVID-19 Pneumonia · COVID-19 Respiratory Infection · Acute Respiratory Failure
Primary: Survival — 9; 5 Participants
Congenital Heart Disease
Primary: Total Units of Intraoperative Allogenic Donor Transfusions (ADT) Administered During Procedure Through ICU Arrival. — 5; 4 ADT units
Bleeding Disorder · Hypofibrinogenemia; Acquired
Primary: Intra-operative Blood Loss — 1380.7; 1660.13 mL — p=<0.001
COVID19
Primary: Number of Participants With Inflammatory Marker Reduction of at Least 50% at Any Efficacy Time Point — 5; 8 Participants — p=0.16
Coronary Artery Disease · Edema
Primary: Extravascular Lung Water Index — 9; 8; 9; 8 mL/kg
Coronary Artery Bypass
Primary: In Hospital Mortality — 0; 4 participants — p=0.142
Influenza A Virus Infection
Primary: Clinical Status at Day 7 — 2; 2; 15; 10 Participants — p=0.54
Immune Thrombocytopenic Purpura
Primary: Set of Antibodies Most Frequently Bound to Red Blood Cells (RBCs) in Subjects Experiencing Clinically Significant Intravascular Hemolysis
Total Fluid Volume Increased
Primary: Concentration of NGAL in Urine on 5 Time Point — 5.6; 4.9; 5.2; 5.1 ng/ml
Cardiac Surgery · Cardiopulmonary Bypass
Primary: Percentage of Subjects With Any Component of a Major Morbidity Composite — 68; 58 Participants
Elective Cardiac Surgical Interventions
Primary: IL-6 — 0; 0; 0; 0 pg/ml
Influenza A · Influenza B
Primary: Time to Normalization of Respiratory Status (Primary Efficacy Population) — 7; 28 days — p=0.069